Trials / Conditions / Metastatic Head and Neck Cancer

Metastatic Head and Neck Cancer

19 registered clinical trials studyying Metastatic Head and Neck Cancer — 4 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Pembrolizumab Plus Ultrasound-Induced Microbubble Cavitation in Head and Neck Cancer NCT07501650	Thomas Jefferson University	Phase 1
Active Not Recruiting	Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinom NCT06790966	PDS Biotechnology Corp.	Phase 3
Recruiting	Cetuximab Plus Platinum and Taxane-based Chemotherapy, Followed by Avelumab and Cetuximab, as First-line Treat NCT06869473	Gruppo Oncologico del Nord-Ovest	Phase 2
Recruiting	PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC NCT06239220	Glenn J. Hanna	Phase 2
Active Not Recruiting	Ramucirumab and Pembrolizumab vs Pembrolizumab Monotherapy in PD-L1 Positive Head and Neck Squamous-Cell Carci NCT05980000	Washington University School of Medicine	Phase 2
Unknown	Study Evaluating the Safety and the Efficacy of Combination of Atezolizumab, Tiragolumab and and Stereotactic NCT05259319	Centre Georges Francois Leclerc	Phase 1
Terminated	BEMPEG With Pembrolizumab vs Pembrolizumab Alone in Patients With Metastatic or Recurrent HNSCC (PROPEL-36) NCT04969861	Nektar Therapeutics	Phase 2 / Phase 3
Active Not Recruiting	Immunotherapy Clearance and Phenotype of Circulating Tumor Cells in Lung and Head and Neck Cancers NCT05091190	Hospices Civils de Lyon	N/A
Completed	Duvelisib Plus Docetaxel In Recurrent/Metastatic HNSCC NCT05057247	Glenn J. Hanna	Phase 2
Completed	A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Recurrent/Metastatic Head and Nec NCT04902027	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.	Phase 1
Completed	Study of PDS0101 and Pembrolizumab Combination I/O in Subjects With HPV16 + Recurrent and/or Metastatic HNSCC NCT04260126	PDS Biotechnology Corp.	Phase 2
Recruiting	A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With NCT04534205	BioNTech SE	Phase 2 / Phase 3
Terminated	Adoptive Cell Transfer of Autologous Tumor Infiltrating Lymphocytes and High-Dose Interleukin 2 in Select Soli NCT03991741	Gregory Daniels	Phase 1
Terminated	Efficacy and Safety Trial of ADU-S100 and Pembrolizumab in Head and Neck Cancer NCT03937141	Chinook Therapeutics, Inc. (formerly Aduro)	Phase 2
Withdrawn	Phase II Trial Assessing the Efficacy of Immuno-Radiation Abscopal Effect in Patients With Metastatic Cancers NCT03323424	Institut de Cancérologie de la Loire	Phase 2
Unknown	Prophylaxis of Magnesium-rich Mineral Water to Prevent Hypomagnesemia Induced by an Anti-EGFR (OPTIMAG) NCT03146338	Weprom	N/A
Completed	A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of NCT02358031	Merck Sharp & Dohme LLC	Phase 3
Completed	A Phase II, Open-Label, Multicenter Trial of Cabazitaxel in Patients With Recurrent or Metastatic Head and Nec NCT01620242	UNICANCER	Phase 2
Terminated	Phase III Trial Of Docetaxel Versus Docetaxel Plus ZD1839 In Head And Neck Cancer NCT00088907	National Cancer Institute (NCI)	Phase 3